Please login to the form below

Not currently logged in
Email:
Password:

Novartis' Owen Wallace to lead Fulcrum Therapeutics

The US biotech has also appointed Sanofi's Amit Hasija

Fulcrum Therapeutics has appointed Owen Wallace as its chief scientific officer in a role that will see him lead the US biotech's efforts in gene regulation.

Wallace has previously served global pharmaceutical companies such as Bristol-Myers Squibb (BMS), Eli Lilly and subsequently at Novartis as its head, global discovery chemistry.

He said: “I am thrilled to be joining Fulcrum in its efforts to pioneer its bold new approach to modulating gene expression to treat the fundamental causes of rare genetic diseases.”

“I look forward to leading Fulcrum’s scientific efforts to harness our understanding of the genetic basis of severe rare disorders and develop innovative new treatments for patients and their families affected by these devastating diseases.”

As part of its leadership team changes Fulcrum has also appointed Amit Hasija, who joins as its chief business officer.

He said: “Fulcrum is uniquely committed to its mission of delivering a new future to patients suffering from severe genetic diseases.

“I’m eager to guide our strategic initiatives as we work to realise the great potential of the company’s innovative product engine and bring life-changing treatments to patients in need.”

Prior to his new role, Hasija worked for Sanofi as its vice president and head integrated care and vice president and head of business development for North America.

Commenting on the two appointments, Fulcrum’s president and CEO Robert Gould said: “We are pleased to be strengthening our leadership team with these key hires.

“Owen brings more than two decades of experience in drug discovery and development across multiple disease areas, including an impressive track record of delivering innpvative compounds into clinical development.

“Amit is a respected industry leader with a wide breadth of finance, strategy and business development experience in the life sciences sector.

“Together, their deep expertise in their respective fields will prove invaluable to Fulcrum as we build and expand our product engine and advance our lead programmes.”

11th May 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics